期刊文献+

芳香化酶抑制剂的临床应用进展

下载PDF
导出
摘要 芳香化酶抑制剂显著、特异抑制雌激素的合成,在治疗乳腺癌、子宫内膜异位症(EMs)、促排卵、晚期复发性子宫内膜癌等各方面的临床应用越来越广泛,同时其不良反应也备受人们关注。
出处 《海峡药学》 2009年第8期10-13,共4页 Strait Pharmaceutical Journal
  • 相关文献

参考文献26

  • 1Simp son ER,Clyne C,Rubin G,et al.Aromatase-abrief overview[J].Annu Rev Physiol,2002,64 (1):93-127.
  • 2Kaufmann M,Bajetta E,Dirix LY,et al.Exemestane is superior to Megestrol Acetate after tamoxifen failure in postmenopausal women with advanced breast cancer:results of a phase Ⅲ randomized doubleblind trial.J Clin Oncol,2000,18(7):1399-1411.
  • 3BaumM,Buzdar A,Cuzick J,et al.Anatrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer:results of the ATAC (Arimidex,Tamoxifen Alone or in combination)trim efficacy and safety update analyses.Cancer,2003,98(9):1802-1810.
  • 4Early Breast Cancer Trialists' Colhhorative Group.Tamoxifen for early breast cancer,an overview of the randomized trials[J].Lancet,1998; 351(9114):1451-1467.
  • 5Baum M,Budzar AU,Cuziek J,et al.Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer.First results of the ATAC randomized trial[J].Lancet,2002,359(9324):2131-2139.
  • 6Goss PE,Ingle JN,Martino S,et al.Randomized placebo-controlled trial of letrosole in postmenopausal women with early breast cancer completing five years of tamoxifen Abstr[J].B resst Cancer Res Treat,2003,82(supple 1):42.
  • 7Dom bernow sky P,Smith I,Falk sonG,et al Fortheletroso le AR/BCZ International Study Group.Double blind random izedphase Ⅱ b/Ⅲ trialoftwodo sesofletrozo leandmegestro lacetate essecond line treatment for patients with breast cancer (abstr)[J].Ann Onco 1,1996,7(supp 15):820.
  • 8Budzar AU,Jones SE,Vogel CL,et al.A phase Ⅲ trial comparing anastrozole (1mg,10mg),a potent and selective aromatase inhibitor,with megestrol acetate in postmenopaueal women with advanced breast cancinoma.Cancer,1997,79:730-739.
  • 9徐兵河.第三代芳香化酶抑制剂在乳腺癌术后辅助治疗中的应用进展[J].中国癌症杂志,2005,15(1):72-74. 被引量:2
  • 10Bulun SE,Gurates B,Fang Z,et al.Mechanisms of excessive estrogen formation in endometriceis.J Reprod Immunol,2002,55(1-2):21-33.

二级参考文献26

  • 1[1]Juad HL, Shanonki IM, frumar AM, et al. Origin of serum estrodial in postmenopausual women. Obstet Gynecol, 1982,59:680-686.
  • 2[2]Budzar AU, Jones SE, Vogel CL, et al. A phase Ⅲ trial comparing anastrozole(1mg, 10mg), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast cancinoma. Cancer, 1997, 79:730-739.
  • 3[3]Rose P, Brunetto VL, VanLe L, et al. A phase Ⅱ trial of anastrozole in advanced recurrent or persistant endometrial carcinoma,a Gynecologic Oncology Group Study. Gynecologic Oncol, 2000,78:212-216.
  • 4[4]Noberasco C, Bajetta E, Zilembo N, et al. Activity of formaestane in de novo tomoxifen-resistant patients with metastatic breast cancer. Oncology,1995, 52:454-457.
  • 5[5]Murray R,Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat, 1995,35:249-253.
  • 6[1]DOWSETT M.Origin and characteristics of adverse events in aromatase inhibition therapy for breast cancer[J].Seminars in Oncology,2003,30(4):58-69.
  • 7[2]BRUEGGEMEIER RW.Aromatase inhibitors[J].Mechanisms of steroidal inhibitors.Breast cancer Res Treat,1994,30:31-42.
  • 8[3]VAN DEN BOSSCHE HV,MOEREELS H,KOYMANS LM.Aromatase inhibitors-Mechanisms of non-steroidal inhibitors[J].Breast cancer Res Treat,1994,30:43-55.
  • 9[4]JONES S,VOGEL C,ARKHIPOV A,et al.Multiple,phase Ⅱ trail of exemestane as third-line hormonal theapy of postmenopausal women with metastatc breast cancer.Aromasin Study Group[J].J Clin Oncol,1999,17:3418-3425.
  • 10[5]KAUMANN M.Steroidal side effects of exenestane[J].J Clin Oncol,2001,19:2107-2108.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部